1
Jun
2023

Pfizer’s RSV Vaccine OK’d, Coherus Challenges Humira, & Eikon Gets a Pipeline

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Maze Bounces Back, TSLP Investment Surges, & Biosecure Breather
AlphaFold3 Dazzles, a Gene Therapy for Deafness, & Pfizer’s New Strategist
Novartis Doubles Down on Radiopharma, Activation Lethality and FTC Nastygrams
Day One’s Home Run, Big Pharma’s Missed Opportunity, and Tessier-Lavigne Rides Again